UOC Infectious Diseases, 9333ASST Papa Giovanni XXII, Bergamo Italy.
FROM foundation, ASST Papa Giovanni XXII, Bergamo Italy.
J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221101815. doi: 10.1177/23259582221101815.
adherence and forgiveness are key factors for virologic success. We evaluated them for 3TC/DTG. pharmacy refills were used to calculate the proportion of days covered (PDC). Forgiveness was calculated as the achieved rate of HIV-RNA threshold by a given level of imperfect adherence. 240 PLWH were included. The median follow-up was 819 days (IQR 450-1459) for a total of 681 person/years of follow-up. Adherence was very high with a median of 99% (IQR 95%-100%). Consequently, the virologic response was sustained with 83.8% of PLWH never exceeding a HIV RNA of 50 copies/ml and 95.8% of subjects with a steadily HIV-RNA < 200 copies/ml. A PDC lower than 80% was associated with a negative outcome irrespective of the HIV-RNA threshold considered. The extensive virologic efficacy of 3TC/DTG demonstrated both in clinical trials and real-world experiences seems to rely more on its friendliness than on its forgiveness.
依从性和宽容度是病毒学成功的关键因素。我们评估了它们在 3TC/DTG 中的作用。通过计算药物补充的比例（PDC）来评估宽容度。宽容度是通过给定的不完美依从性水平实现 HIV-RNA 阈值的比例来计算的。共纳入 240 名 PLWH。中位随访时间为 819 天（IQR 450-1459），总随访时间为 681 人/年。依从性非常高，中位数为 99%（IQR 95%-100%）。因此，病毒学反应持续，83.8%的 PLWH 从未超过 50 拷贝/ml 的 HIV RNA，95.8%的患者 HIV-RNA<200 拷贝/ml 稳定。无论考虑何种 HIV-RNA 阈值，PDC 低于 80%与不良结果相关。3TC/DTG 在临床试验和真实世界经验中的广泛疗效似乎更多地依赖于其友好性，而不是宽容度。
